Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Vericel Corporation (VCEL)
:VCEL
Holding VCEL?
Track your performance easily
VCEL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$38.69 - $61.49
Previous CloseN/A
Volume83.17K
Average Volume (3M)385.86K
Market Cap
$2.78B
Enterprise Value$2.05B
Total Cash (Recent Filing)$22.98M
Total Debt (Recent Filing)$9.35M
Price to Earnings (P/E)945.1
Beta1.38
Next Earnings
Mar 04, 2025EPS Estimate
0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.06
Shares Outstanding49,358,410
10 Day Avg. Volume492,673
30 Day Avg. Volume385,863
Standard Deviation0.16
R-Squared0.31
Alpha0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)12.26
Price to Cash Flow (P/CF)68.30
P/FCF Ratio0.00
Enterprise Value/Market Cap0.74
Enterprise Value/Revenue9.05
Enterprise Value/Gross Profit15.14
Enterprise Value/Ebitda58.66K
Forecast
1Y Price Target
$63.57Price Target Upside7.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Vericel News
PremiumCompany Announcements
Vericel Projects Strong Growth and Profitability Ahead
Ownership Overview
0.89% Insiders
35.38% Mutual Funds
0.79% Other Institutional Investors
40.13% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VCEL FAQ
What was Vericel Corporation’s price range in the past 12 months?
Vericel Corporation lowest stock price was $38.69 and its highest was $61.49 in the past 12 months.
What is Vericel Corporation’s market cap?
Vericel Corporation’s market cap is $2.78B.
When is Vericel Corporation’s upcoming earnings report date?
Vericel Corporation’s upcoming earnings report date is Mar 04, 2025 which is in 42 days.
How were Vericel Corporation’s earnings last quarter?
Vericel Corporation released its earnings results on Nov 07, 2024. The company reported -$0.02 earnings per share for the quarter, beating the consensus estimate of -$0.048 by $0.028.
Is Vericel Corporation overvalued?
According to Wall Street analysts Vericel Corporation’s price is currently Undervalued.
Does Vericel Corporation pay dividends?
Vericel Corporation does not currently pay dividends.
What is Vericel Corporation’s EPS estimate?
Vericel Corporation’s EPS estimate is 0.3.
How many shares outstanding does Vericel Corporation have?
Vericel Corporation has 49,358,410 shares outstanding.
What happened to Vericel Corporation’s price movement after its last earnings report?
Vericel Corporation reported an EPS of -$0.02 in its last earnings report, beating expectations of -$0.048. Following the earnings report the stock price went up 4.142%.
Which hedge fund is a major shareholder of Vericel Corporation?
Currently, no hedge funds are holding shares in VCEL
---
Vericel Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$63.57 (7.62% Upside)
$63.57 (7.62% Upside)
Blogger Sentiment
Bullish
VCEL Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 17.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $152.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.6%
Last 30 Days ▲ 14.9%
Last 30 Days ▲ 14.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
56.14%
12-Months-Change
Fundamentals
Return on Equity
1.54%
Trailing 12-Months
Asset Growth
22.72%
Trailing 12-Months
Company Description
Vericel Corporation
Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. Its product portfolio includes MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.
---
VCEL Company Deck
---
VCEL Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
Vericel had a strong third quarter with significant revenue growth, margin expansion, and key regulatory approvals. Despite reporting a net loss and increased operating expenses, the company's financial performance was robust, with strong cash flow and a positive outlook for future growth.Read More>---
VCEL Stock 12 Month Forecast
Average Price Target
$63.57
▲(7.62% Upside)
Technical Analysis
AxoGen
―
Crispr Therapeutics AG
―
Fate Therapeutics
―
Bluebird Bio
―
Editas Medicine
―
Intellia Therapeutics
―
Best Analysts Covering VCEL
1 Year
1 Year Success Rate
14/14 ratings generated profit
1 Year Average Return
+35.90%
reiterated a buy rating 7 days ago
Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +35.90% per trade.
---